Bristol-Myers Squibb Company

Event Bristol-Myers Squibb Company (BMY) Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) Trial met its primary endpoint, demonstrating clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 Mar 29, 2026 Event Bristol-Myers Squibb Company (BMY) Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy (xanomeline and trospium chloride) Mar 28, 2026 Event Bristol-Myers Squibb Company (BMY) Three New Studies Show Viz.ai’s Cardio Suite Speeds Detection of Cardiac Disease and Improves Patient Follow-Up Mar 23, 2026 News BioNTech (BNTX) Reports Q4 Loss of EUR0.33/Share as COVID Vaccine Revenue Plunges; Founders Exit Mar 11, 2026 Transcript Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Call Transcript Jan 22, 2026 Transcript Bristol-Myers Squibb Company (BMY) Q3 2025 Earnings Call Transcript Jan 22, 2026 News Bristol Myers Squibb (BMY) Earnings: 3Q25 Key Numbers Oct 30, 2025 News Bristol Myers Squibb (BMY) Earnings: 2Q25 Key Numbers Jul 31, 2025